Analyst Viewpoint
Increase in prevalence of kidney infection is one of the key factors boosting the global focal segmental glomerulosclerosis market size. A person suffering from kidney disease is at higher risk of contracting focal segmental glomerulosclerosis, as both kidney diseases and focal segmental glomerulosclerosis are interrelated. Advancements in R&D are also augmenting the focal segmental glomerulosclerosis industry growth. Various treatments are being developed for focal segmental glomerulosclerosis, including stem cell therapy and genetic therapies.
Companies in the global landscape are striving to develop specialized diagnostic tests and treatments to improve the prognosis of patients with this disease. In line with the latest focal segmental glomerulosclerosis market, key players are also engaged in product launches and product approvals to increase their industry share.
Focal segmental glomerulosclerosis (FSGS) is a type of kidney disease characterized by the formation of scar tissue on the glomeruli, the filtering part of the kidney that eliminates waste from the body.
FSGS causes aberrant protein loss in the urine and impairment in the kidneys' filtration capacity. The condition is most commonly characterized by frothy urine, excessive water retention, infection susceptibility, and fatty casts in the urine.
Some of the common causes of FSGS are kidney diseases, obesity, excessive intake of drugs or steroids, and inherited genetic issues. The condition affects men more than women. People with FSGS may also gain weight due to high blood fat levels. Furthermore, they may experience low appetite, exhaustion, and the accumulation of extra fluid in the body.
A combination of imaging studies and laboratory tests are usually used to diagnose FSGS. CT scan or ultrasound helps in detecting any abnormalities and impairment in the kidneys.
Laboratory tests are performed to check the levels of high creatinine, while a urine test helps diagnose proteinuria. Additionally, renal biopsy may be necessary to confirm FSGS in patients. This procedure involves taking a small sample of the kidney with a specific needle and examining it under a microscope.
Kidney infection is a type of urinary tract infection (UTI) that may begin in a different part of the urinary tract, such as the urethra (tube that carries urine from the body) or bladder, and travel to one or both kidneys.
According to the Centers for Disease Control and Prevention, around 37 million Americans or about 15% of the population in the U.S. is estimated to suffer from chronic kidney disease. In 2021, the frequency was 6% among those between the ages of 18 and 44, and 12% among those between the ages of 45 and 64. Thus, increase in incidence of kidney infections is one of the key focal segmental glomerulosclerosis market drivers.
Growth in spending capacity on healthcare is aiding in the creation and accessibility of medications for focal segmental glomerulosclerosis. Rise in funding for clinical trials and research, which enhance the production of new drugs, is also augmenting the focal segmental glomerulosclerosis industry.
As per a report released in May 2023 by the Office for National Statistics, the U.K. Government agency, healthcare spending in the U.K. increased by 9.4% in nominal terms and 9.7% in real terms between 2020 and 2021. Additionally, the U.K. spent £280.7 Bn (US$ 367.25 Bn) on healthcare, £39.6 Bn (US$ 51.84 Bn) on pharmaceuticals, and £35.1 Bn (US$ 45.93 Bn) on preventative care in 2021-more than doubling the amount spent in 2020.
Thus, increase in healthcare spending is creating lucrative focal segmental glomerulosclerosis market opportunities for companies operating in the sector.
As per the latest focal segmental glomerulosclerosis market analysis, North America accounted for the largest share in 2022. Presence of developed economies, availability of modern medical facilities, and surge in adoption of high-end technology are driving the growth of the focal segmental glomerulosclerosis industry in the region.
As per focal segmental glomerulosclerosis market research, the U.S. constitutes significant share of the sector in North America. According to Evaluate Ltd., around 40,000 people in the U.S. were afflicted with FSGS in 2021.
Ongoing clinical trials by manufacturers and rise in research activities are anticipated to spur the market dynamics of North America. Majority of manufacturers worldwide are opting to conduct clinical trials and research in the U.S. owing to the favorable geographical position and governmental policies in the country.
Increase in investment in research and development activities is a prominent focal segmental glomerulosclerosis marketing strategy adopted by the leading players in the global landscape. Key players are also entering into partnership and collaboration agreements to expand their product portfolio.
Variant Pharmaceuticals, Inc., ChemoCentryx, Inc., Travere Therapeutics, AbbVie, Inc., Novartis AG, Pfizer, Inc., AstraZeneca plc., Sanofi S.A., GlaxoSmithKline plc., are Teva Pharmaceutical Industries Ltd. are the leading players operating in the global landscape.
Each of these firms have been profiled in the focal segmental glomerulosclerosis market report based on parameters such as company overview, business strategies, financial overview, business segments, product portfolio, and recent developments.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 538.5 Mn |
| Market Forecast (Value) in 2031 | US$ 956.2 Mn |
| Growth Rate (CAGR) | 6.5% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Mn for Value |
| Market Analysis | It includes segment analysis as well as regional-level analysis. Furthermore, the qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 538.5 Mn in 2022
It is anticipated to grow at a CAGR of 6.5% from 2023 to 2031
Increase in prevalence of kidney infection and rise in healthcare expenditure
The primary focal segmental glomerulosclerosis segment accounted for the largest share in 2022
North America was the leading region in 2022
Variant Pharmaceuticals, Inc., ChemoCentryx, Inc., Travere Therapeutics, AbbVie, Inc., Novartis AG, Pfizer, Inc., AstraZeneca plc., Sanofi S.A., GlaxoSmithKline plc., and Teva Pharmaceutical Industries Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Focal Segmental Glomerulosclerosis Market
4. Market Overview
4.1. Introduction
4.1.1. Disease Type Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Disease Type/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, by Disease Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Disease Type, 2017–2031
6.3.1. Primary Focal Segmental Glomerulosclerosis
6.3.2. Secondary Focal Segmental Glomerulosclerosis
6.4. Market Attractiveness Analysis, by Disease Type
7. Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, by Disease Management
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Disease Management, 2017–2031
7.3.1. Diagnosis
7.3.1.1. Kidney Biopsy
7.3.1.2. Creatinine Test
7.3.1.3. Others
7.3.2. Treatment
7.3.2.1. Drug Therapy
7.3.2.2. Dialysis
7.3.2.3. Kidney Transplant
7.4. Market Attractiveness Analysis, by Disease Management
8. Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2017–2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Focal Segmental Glomerulosclerosis Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Disease Type, 2017–2031
9.3.1. Primary Focal Segmental Glomerulosclerosis
9.3.2. Secondary Focal Segmental Glomerulosclerosis
9.4. Market Value Forecast, by Disease Management, 2017–2031
9.4.1. Diagnosis
9.4.1.1. Kidney Biopsy
9.4.1.2. Creatinine Test
9.4.1.3. Others
9.4.2. Treatment
9.4.2.1. Drug Therapy
9.4.2.2. Dialysis
9.4.2.3. Kidney Transplant
9.5. Market Value Forecast, by Country, 2017–2031
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Disease Type
9.6.2. By Disease Management
9.6.3. By Country
10. Europe Focal Segmental Glomerulosclerosis Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Disease Type, 2017–2031
10.3.1. Primary Focal Segmental Glomerulosclerosis
10.3.2. Secondary Focal Segmental Glomerulosclerosis
10.4. Market Value Forecast, by Disease Management, 2017–2031
10.4.1. Diagnosis
10.4.1.1. Kidney Biopsy
10.4.1.2. Creatinine Test
10.4.1.3. Others
10.4.2. Treatment
10.4.2.1. Drug Therapy
10.4.2.2. Dialysis
10.4.2.3. Kidney Transplant
10.5. Market Value Forecast, by Country/Sub-region, 2017–2031
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Italy
10.5.5. Spain
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Disease Type
10.6.2. By Disease Management
10.6.3. By Country/Sub-region
11. Asia Pacific Focal Segmental Glomerulosclerosis Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Disease Type, 2017–2031
11.3.1. Primary Focal Segmental Glomerulosclerosis
11.3.2. Secondary Focal Segmental Glomerulosclerosis
11.4. Market Value Forecast, by Disease Management, 2017–2031
11.4.1. Diagnosis
11.4.1.1. Kidney Biopsy
11.4.1.2. Creatinine Test
11.4.1.3. Others
11.4.2. Treatment
11.4.2.1. Drug Therapy
11.4.2.2. Dialysis
11.4.2.3. Kidney Transplant
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Disease Type
11.6.2. By Disease Management
11.6.3. By Country/Sub-region
12. Latin America Focal Segmental Glomerulosclerosis Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Disease Type, 2017–2031
12.3.1. Primary Focal Segmental Glomerulosclerosis
12.3.2. Secondary Focal Segmental Glomerulosclerosis
12.4. Market Value Forecast, by Disease Management, 2017–2031
12.4.1. Diagnosis
12.4.1.1. Kidney Biopsy
12.4.1.2. Creatinine Test
12.4.1.3. Others
12.4.2. Treatment
12.4.2.1. Drug Therapy
12.4.2.2. Dialysis
12.4.2.3. Kidney Transplant
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Disease Type
12.6.2. By Disease Management
12.6.3. By Country/Sub-region
13. Middle East & Africa Focal Segmental Glomerulosclerosis Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Disease Type, 2017–2031
13.3.1. Primary Focal Segmental Glomerulosclerosis
13.3.2. Secondary Focal Segmental Glomerulosclerosis
13.4. Market Value Forecast, by Disease Management, 2017–2031
13.4.1. Diagnosis
13.4.1.1. Kidney Biopsy
13.4.1.2. Creatinine Test
13.4.1.3. Others
13.4.2. Treatment
13.4.2.1. Drug Therapy
13.4.2.2. Dialysis
13.4.2.3. Kidney Transplant
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
13.6.1. By Disease Type
13.6.2. By Disease Management
13.6.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. Variant Pharmaceuticals, Inc.
14.3.1.1. Company Overview
14.3.1.2. Disease Type Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.2. ChemoCentryx, Inc.
14.3.2.1. Company Overview
14.3.2.2. Disease Type Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Financial Overview
14.3.2.5. Strategic Overview
14.3.3. Travere Therapeutics
14.3.3.1. Company Overview
14.3.3.2. Disease Type Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Financial Overview
14.3.3.5. Strategic Overview
14.3.4. AbbVie, Inc.
14.3.4.1. Company Overview
14.3.4.2. Disease Type Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Financial Overview
14.3.4.5. Strategic Overview
14.3.5. Novartis AG
14.3.5.1. Company Overview
14.3.5.2. Disease Type Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Financial Overview
14.3.5.5. Strategic Overview
14.3.6. Pfizer, Inc.
14.3.6.1. Company Overview
14.3.6.2. Disease Type Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Financial Overview
14.3.6.5. Strategic Overview
14.3.7. AstraZeneca plc.
14.3.7.1. Company Overview
14.3.7.2. Disease Type Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Financial Overview
14.3.7.5. Strategic Overview
14.3.8. Sanofi S.A.
14.3.8.1. Company Overview
14.3.8.2. Disease Type Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Financial Overview
14.3.8.5. Strategic Overview
14.3.9. GlaxoSmithKline plc.
14.3.9.1. Company Overview
14.3.9.2. Disease Type Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Financial Overview
14.3.9.5. Strategic Overview
14.3.10. Teva Pharmaceutical Industries Ltd.
14.3.10.1. Company Overview
14.3.10.2. Disease Type Portfolio
14.3.10.3. SWOT Analysis
14.3.10.4. Financial Overview
14.3.10.5. Strategic Overview
List of Tables
Table 01: Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2017–2031
Table 02: Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2017–2031
Table 03: Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 04: North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 05: North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2017–2031
Table 06: North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2017–2031
Table 07: Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 8: Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2017–2031
Table 9: Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2017–2031
Table 10: Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 11: Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2017–2031
Table 12: Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2017–2031
Table 13: Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2017–2031
Table 15: Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2017–2031
Table 16: Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2017–2031
Table 18: Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2017–2031
List of Figures
Figure 01: Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
Figure 02: Global Focal Segmental Glomerulosclerosis Market Revenue (US$ Mn), by Disease Type, 2022
Figure 03: Global Focal Segmental Glomerulosclerosis Market Value Share, by Disease Type, 2022
Figure 04: Global Focal Segmental Glomerulosclerosis Market Revenue (US$ Mn), by Disease Management, 2022
Figure 05: Global Focal Segmental Glomerulosclerosis Market Value Share, by Disease Management, 2022
Figure 06: Global Focal Segmental Glomerulosclerosis Market Value Share, by Region, 2022
Figure 07: Global Focal Segmental Glomerulosclerosis Market Value (US$ Mn) Forecast, 2017–2031
Figure 08: Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2022 and 2031
Figure 09: Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2023-2031
Figure 10: Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2023 and 2031
Figure 11: Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2023-2031
Figure 12: Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Region, 2022 and 2031
Figure 13: Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Region, 2023-2031
Figure 14: North America Focal Segmental Glomerulosclerosis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 15: North America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country, 2023–2031
Figure 16: North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country, 2022 and 2031
Figure 17: North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2022 and 2031
Figure 18: North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2022 and 2031
Figure 19: North America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2023–2031
Figure 20: North America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2023–2031
Figure 21: Europe Focal Segmental Glomerulosclerosis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 22: Europe Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 23: Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 24: Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2022 and 2031
Figure 25: Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2022 and 2031
Figure 26: Europe Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2023–2031
Figure 27: Europe Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2023–2031
Figure 28: Asia Pacific Focal Segmental Glomerulosclerosis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 29: Asia Pacific Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 30: Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 31: Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2022 and 2031
Figure 32: Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2022 and 2031
Figure 33: Asia Pacific Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2023-2031
Figure 34: Asia Pacific Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2023–2031
Figure 35: Latin America Focal Segmental Glomerulosclerosis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 36: Latin America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 37: Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 38: Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2022 and 2031
Figure 39: Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2022 and 2031
Figure 40: Latin America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2023–2031
Figure 41: Latin America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2023–2031
Figure 42: Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 43: Middle East & Africa Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 44: Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 45: Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2022 and 2031
Figure 46: Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2022 and 2031
Figure 47: Middle East & Africa Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2023–2031
Figure 48: Middle East & Africa Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Focal Segmental Glomerulosclerosis Market
